Ozempic and Eye Health: Vision Changes, NAION & Risks

Ozempic, Wegovy, and Zepbound: Can Weight-Loss Medications Affect Your Eyes?

What patients should know about GLP-1 medications, vision changes, diabetic retinopathy, and the latest research on optic nerve health.

Weight-loss medications such as Ozempic, Wegovy, and Zepbound are transforming the treatment of obesity and Type 2 diabetes. These medications can help patients achieve significant weight loss, improve blood sugar control, and reduce certain cardiovascular risks.

But as their popularity increases, an important question has emerged:

Can GLP-1 medications affect your eyesight?

At Precision Eye Care in Baltimore, Maryland, we believe patients should understand both the benefits and potential risks of these medications, particularly when it comes to protecting their vision.

What Are GLP-1 Medications?

GLP-1 receptor agonists mimic a naturally occurring hormone that helps regulate appetite and blood sugar. They can reduce hunger, increase feelings of fullness, and improve glucose control.

Commonly prescribed medications include:

• Ozempic (semaglutide): Primarily prescribed for Type 2 diabetes.
• Wegovy (semaglutide): Approved for chronic weight management and certain additional indications.
• Zepbound (tirzepatide): Approved for chronic weight management and obstructive sleep apnea in eligible adults.

Unlike semaglutide, tirzepatide acts on two hormonal pathways: GLP-1 and GIP.

Although these medications offer substantial health benefits, researchers are continuing to investigate their effects on the eyes.

Can Ozempic or Wegovy Cause Vision Problems?

Most patients taking GLP-1 medications do not develop serious eye complications. However, several conditions deserve attention.

1. Diabetic Retinopathy and Rapid Blood Sugar Changes

For patients with diabetes, improving blood sugar control is one of the most important ways to protect long-term vision. However, a rapid reduction in blood glucose can sometimes temporarily worsen existing diabetic retinopathy, especially in patients with advanced retinal disease or previously poorly controlled diabetes.

This phenomenon is not unique to GLP-1 medications. The prescribing information for semaglutide includes warnings about diabetic retinopathy complications and recommends monitoring patients with a history of diabetic retinopathy.

Our recommendation: Patients with diabetes should maintain regular dilated eye examinations. Those with existing diabetic retinopathy may require closer monitoring when starting or increasing treatment.

2. Ozempic, Wegovy, and NAION: What Does the Latest Research Show?

Recent studies have identified a potential association between semaglutide and a rare condition called nonarteritic anterior ischemic optic neuropathy (NAION). NAION occurs when blood supply to part of the optic nerve is insufficient, potentially resulting in sudden, usually painless vision loss in one eye.

In 2025, the European Medicines Agency concluded that NAION should be classified as a very rare adverse effect of semaglutide, with an estimated frequency of up to one additional case per 10,000 patients treated for one year.

The World Health Organization also issued a safety communication about this potential risk. Although observational research has reported an association, the precise biological mechanism and individual risk factors remain under investigation.

These findings do not mean that most patients taking semaglutide will experience vision loss. The absolute risk is low, and the medication’s benefits may outweigh its risks for many patients.

Important: Sudden vision loss is a medical emergency. Seek immediate ophthalmic or emergency medical evaluation. Patients with suspected NAION should also contact their prescribing clinician immediately regarding semaglutide treatment.

3. Blurry Vision and Blood Sugar Fluctuations

Some patients with diabetes notice temporary blurry vision when their blood sugar levels change rapidly. These fluctuations can affect the natural lens of the eye, temporarily changing how light is focused.

Vision may stabilize as blood sugar levels become more consistent. However, not all blurry vision is caused by glucose changes. Other conditions, including cataracts, diabetic macular edema, and retinal disease, may produce similar symptoms.

Persistent or worsening vision changes should be evaluated by an eye care professional.

Could GLP-1 Medications Actually Benefit Eye Health?

Potentially. Improving blood sugar control and cardiovascular health may reduce the long-term risk of complications associated with diabetes. Researchers are also investigating whether GLP-1 medications have beneficial effects on retinal inflammation, vascular function, and nerve tissue.

However, these possible protective effects remain under investigation. GLP-1 medications are not established treatments for diabetic retinopathy, glaucoma, or optic nerve disease.

Should You Have an Eye Examination Before Starting Ozempic or Wegovy?

Not everyone starting a GLP-1 medication needs a special eye examination solely because of the prescription.

However, an eye examination is particularly important if you:

• Have Type 1 or Type 2 diabetes.
• Have been diagnosed with diabetic retinopathy.
• Have experienced unexplained blurry vision.
• Have a history of retinal or optic nerve disease.
• Are overdue for your recommended comprehensive eye examination.

Patients with diabetes should follow their ophthalmologist’s recommendations for regular retinal screening, even when blood sugar levels are improving.

Protecting Your Vision While Improving Your Health

GLP-1 medications represent an important advancement in the treatment of obesity and diabetes. For many patients, the health benefits are substantial. Understanding possible eye-related complications helps patients make informed decisions and recognize when medical attention is necessary.

At Precision Eye Care in Baltimore, Maryland, we provide comprehensive eye examinations and evaluations for diabetic eye disease, cataracts, glaucoma, and other conditions affecting vision.

If you are taking Ozempic, Wegovy, Zepbound, or another weight-loss medication and have questions about your eye health, our team can help.

Schedule a comprehensive eye examination at Precision Eye Care to protect your vision.

Medical disclaimer: This article is intended for educational purposes and does not replace individualized medical advice. Discuss medication benefits and risks with your prescribing healthcare professional.

References

1. European Medicines Agency. PRAC concludes eye condition NAION is a very rare side effect of semaglutide medicines. 2025.

2. World Health Organization. Semaglutide medicines and risk of non-arteritic anterior ischemic optic neuropathy (NAION). 2025.

3. U.S. Food and Drug Administration. Ozempic (semaglutide) prescribing information.

4. Hathaway JT, et al. Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide. JAMA Ophthalmology. 2024.